MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$496,009,000
Net Income
$486,000
Net Profit Margin
0.10%
Unit: Dollar
Revenue Breakdown
Vivitrol
Aristada And Aristada Initio
LUMRYZ
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
496,009,000
392,911,000
384,547,000
394,185,000
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)
98,112,000
61,578,000
46,209,000
51,591,000
Research and development
112,920,000
103,345,000
93,038,000
81,739,000
Discontinued operations, net of tax
-
-
-
0
Selling, general and administrative
217,625,000
264,593,000
187,196,000
171,773,000
Total revenues-Research And Development
-
-
-
0
Change in fair value of contingent consideration
26,414,000
-
-
-
Amortization of acquired intangible assets
22,585,000
11,675,000
-
0
Total expenses
477,656,000
441,191,000
326,443,000
305,103,000
Operating (loss) income
18,353,000
-48,280,000
58,104,000
89,082,000
Interest income
5,344,000
8,539,000
12,130,000
11,943,000
Interest expense
25,925,000
20,892,000
15,164,000*
0
Other (expense) income, net
352,000
-1,293,000
5,307,000*
-280,000
Total other (expense) income, net
-20,229,000
-13,646,000
2,273,000
11,663,000
(loss) income before income taxes
-1,876,000
-61,926,000
60,377,000
100,745,000
Income tax provision (benefit)
-2,377,000
4,554,000
11,036,000
17,984,000
Net income from continuing operations
-
-
49,341,000
82,761,000
Net (loss) income
501,000
-66,480,000
49,341,000
82,761,000
Holding (loss) gain, net of a tax (benefit) provision of 78, 16, 249 and 184, respectively
-255,000
-568,000
-1,041,000
341,000
Foreign currency translation gain
240,000
-240,000
-
-
Comprehensive (loss) income
486,000
-67,288,000
48,300,000
83,102,000
Basic EPS
0
-0.4
0.292
0.5
Diluted EPS
0
-0.4
0.285
0.49
Basic Average Shares
167,026,000
166,196,000
165,360,000
165,086,000
Diluted Average Shares
173,478,000
166,196,000
169,368,000
168,510,000
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Vivitrol
$124,454,000
Aristada And Aristada
Initio
$96,719,000
LUMRYZ
$96,572,000
LYBALVI
$93,979,000
Royalty
$63,384,000
Manufacturing Revenue
$20,901,000
Product
$411,724,000
(34.01%↑ Y/Y)
Manufactured Product And
Royalty
$84,285,000
(1.03%↑ Y/Y)
Income tax provision
(benefit)
-$2,377,000
(-113.40%↓ Y/Y)
Total revenues
$496,009,000
(26.97%↑ Y/Y)
Net (loss) income
$501,000
(-99.42%↓ Y/Y)
Foreign currency
translation gain
$240,000
(loss) income before
income taxes
-$1,876,000
(-101.79%↓ Y/Y)
Operating (loss) income
$18,353,000
(-80.26%↓ Y/Y)
Total expenses
$477,656,000
(60.46%↑ Y/Y)
Comprehensive (loss) income
$486,000
(-99.44%↓ Y/Y)
Holding (loss) gain, net
of a tax (benefit)...
-$255,000
(-563.64%↓ Y/Y)
Total other (expense)
income, net
-$20,229,000
(-270.55%↓ Y/Y)
Interest income
$5,344,000
(-51.81%↓ Y/Y)
Other (expense)
income, net
$352,000
Selling, general and
administrative
$217,625,000
(27.38%↑ Y/Y)
Research and development
$112,920,000
(45.95%↑ Y/Y)
Cost of goods
manufactured and sold...
$98,112,000
(98.37%↑ Y/Y)
Change in fair value of
contingent consideration
$26,414,000
Amortization of acquired
intangible assets
$22,585,000
Interest expense
$25,925,000
Buy us a coffee
Alkermes plc. (ALKS)
Alkermes plc. (ALKS)